TuHURA Biosciences Receives FDA "Study May Proceed" Notice and IND Clearance for the Evaluation of its TBS-2025 VISTA-Inhibiting Antibody in Molecularly Defined Subsets of AML and Other Blood-Related Cancers
TuHURA Biosciences Inc HURA
$2.10
▲ +0.00%
(+$0.00)
Open
$2.14
Prev Close
$2.10
Day Range
$2.05 – $2.15
52W Range
$0.41 – $3.43
Market Cap
$133.83M
Beta
-0.22
EPS (TTM)
$-0.54
📋 Company Profile
| Industry | Biotechnology |
| Country | US |
| Exchange | NASDAQ NMS - GLOBAL MARKET |
| Currency | USD |
| IPO Date | 2016-07-12 |
| Shares Out. | 63,680,000 |
| Website | tuhurabio.com/ ↗ |
| Phone | 18138756600 |
| Employees | 22 |
| Revenue | $0 |
| Gross Profit | $0 |
| Net Income | -$9.2M |
| Free Cash Flow | -$29.9M |
| Total Assets | $31.7M |
| Total Liabilities | $13.2M |
| Equity | $18.5M |
About TuHURA Biosciences Inc
TuHURA Biosciences Inc is a phase 3 clinical stage immuno-oncology company with three distinct technologies focused on the development of novel therapeutics designed to overcome primary and acquired resistance to cancer immunotherapies. The company's personalized cancer vaccine candidate, IFx-2.0, is designed to overcome primary resistance to checkpoint inhibitors. The company operates in one reportable segment, which includes all activities related to advancing therapies for cancer treatment.
TuHURA Biosciences Inc is a publicly traded company under the ticker symbol HURA on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.
📊 Analyst Ratings
10 analysts (2026-09-01)